B-Type natriuretic peptide: From bench to bedside

American Heart Journal

Volumn 145, Issue 2 SUPPL., 2003, Pages

  Adams Jr , Kirkwood F ^a   Mathur, Vandana S ^b   Gheorghiade, Mihai ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ATRIAL NATRIURETIC FACTOR; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CELL SURFACE RECEPTOR; CYCLIC GMP; DENDROASPIS NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; ENDOTHELIN 1; GLYCERYL TRINITRATE; MILRINONE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; NESIRITIDE; NITRATE; NITROPRUSSIDE SODIUM; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANGINA PECTORIS; BLOOD VESSEL TONE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; INOTROPISM; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN SECRETION; PROTEIN STRUCTURE; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME; VERTIGO;

EID: 0037326179     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2003.152     Document Type: Conference Paper

References (53)

1. American Heart Association. 2002 Heart and stroke statistical update. Dallas: American Heart Association; 2002.
2. Burger A, Burger M. BNP in decompensated heart failure: diagnostic, prognostic and therapeutic potential. Curr Opin Investig Drugs 2001;2:929-35.
3. Hobbs RE, Mills RM, Young JB. An update on nesiritide for treatment of decompensated heart failure. Exp Opin Investig Drugs 2001;10:935-42.
4. Colucci WS. Nesiritide for the treatment of decompensated heart failure. J Card Fail 2001;7:92-100.
5. Rocca HPBL, Kiowski W, Ramsay D, et al. Therapeutic benefits of increasing natriuretic peptide levels. Cardiovasc Res 2001;51:510-20.
6. Chen HH, Burnett JC. The natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep 2000;3:198-205.
7. Mattingly MT, Brandt RR, Heublein DM, et al. Presence of C-type natriuretic peptide in human kidney and urine. Kid Internat 1994;46:744-7.
8. Suzuki T, Yamazaki T, Yazaki Y. The role of the natriuretic peptides in the cardiovascular system. Cardiovasc Res 2001;51:489-94.
9. Silberbach M, Roberts C. Natriuretic peptide signaling: molecular and cellular pathways to growth regulation. Cell Signal 2001;13:221-31.
10. Kone BC. Molecular biology of natriuretic peptides and nitric oxide synthases. Cardiovasc Res 2001;51:429-41.
11. Richards M, Lainchbury JG, Nicholls MG, et al. Dendroaspis natriuretic peptide: endogenous or dubious? Lancet 2002;359:5-6.
12. Protter AA, Wallace AM, Ferraris VA, et al. Relaxant effect of human brain natriuretic peptide on human artery and vein tissue. Am J Hypertens 1996;9:432-6.
13. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretlc peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000;343:246-53.
14. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic, hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998;4:37-44.
15. Jensen KT, Carstens J, Pedersen EB. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am J Physiol 1998;274(Suppl):F63-72.
16. LaVilla G, Fronzaroli C, Lazzeri C, et al. Cardiovascular and renal effects of low dose brain natriuretic peptide infusion in man. J Clin Endocrin Metab 1994;78:1166-71.
17. Hirose M, Furukawa Y, Kurogouchi F, et al. C-type natriuretic peptide increases myocardial contractility and sinus rate mediated by guanylyl cylcase-linked natriuretic peptide receptors in isolated, blood-perfused dog heart preparations. J Pharmacol Experiment Therap 1998;286:70-6.
18. Publication Committee for the Vasodilation in the Management of Acute Congestive Heart Failure (VMAC) Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-40.
19. Okumura K, Yasue H, Fujii H, et al. Effects of brain (B-type) natriuretic peptide on coronary artery diameter and coronary hemodynamic variables in humans: comparison with effects on systemic hemodynamic variables. J Am Coll Cardiol 1995;25:342-8.
20. Lai CP, Egashira K, Tashiro H, et al. Beneficial effects of atrial natriuretic peptide on exercise-induced myocardial ischemia in patients with stable effort angina pectoris. Circulation 1993;87:144-51.
21. John SW, Krege JH, Oliver PM, et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 1995;267:679-81.
22. Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci 2000;97:4239-44.
23. Thuerauf DJ, Glembotski CC. Differential effects of protein kinase C, ras, and raf-1 kinase on the induction of the cardiac B-type natriuretic peptide gene through a critical promoter-proximal MCAT element. J Biol Chem 1997;272:7464-72.
24. Schirger JA, Heublein DM, Chen HH, et al. Presence of dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clinic Proc 1999;74:126-30.
25. Ikram H, Chan W, Espiner E, et al. Haemodynamic and hormone responses to acute and chronic furosemide therapy in congestive heart failure. Clin Sci 1980;59:443-9.
26. Shinbane J, Wood M, Hensen D, et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol 1997;29:709-15.
27. Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001;37:1228-33.
28. Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation 1993;88:2277-83.
29. Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 1992;86:431-8.
30. Groenning BA, Nilsson JC, Sondergaard L, et al. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000;36:2072-80.
31. Doughty RN, Whalley GA, Gamble G, et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 1997;29:1060-6.
32. Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure [abstract]. J Clin Inves 1997;99:1926.
33. Gainer JV, Morrow JD, Loveland A, et al. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;18:1285-92.
34. Chen HH, Lainchbury JG, Matsuda Y, et al. Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure. Hypertension 2001;38:187-91.
35. Akabane S, Matsushima Y, Matsuo H, et al. Effects of brain natriuretic peptide on renin secretion in normal and hypertonic saline-infused kidney. Eur J Pharmacology 1991;198:143-8.
36. Kohno M, Yokokawa K, Hrio T, et al. Atrial and brain natriuretic peptides inhibit the endothelin-1 secretory response to angiotensin II in porcine aorta. Circ Res 1992;70:241-7.
37. Abramson BL, Ando S, Notarius CF, et al. Effect of atrial natriuretic peptide on muscle sympathetic activity and its reflex control in human heart failure. Circulation 1999;99:1810-5.
38. Wada A, Tsutamoto T, Matsuda Y, et al. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cydase-coupled receptors. Circulation 1994;89:2232-40.
39. Brunner-La Rocca HP, Kaye DM, Woods RL, et al. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001;37:1221-7.
40. Aronson D, Burger A. Effect of nesiritide on endothelin-1 levels in patients with decompensated congestive heart failure [abstract]. J Am Coll Cardiol 2001;37:148A.
41. Hayashi M, Tsutamoto T, Wada A, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first acute anterior myocardial infaction. J Am Coll Cardiol 2001;37:1820-6.
42. Mills RM, LeJemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 1999;34:155-62.
43. Silver MA, Horton D, Ghali J, et al. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 2002;39:798-803.
44. Hobbs RE, Miller LW, Bott-Silverman C, et al. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996;78:896-901.
45. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: a double-blind, placebo-controlled, randomized crossover trial. Circulation 1996;94:3184-9.
46. Burger AJ, Dennish G, Dinerman J, et al. Nesiritide therapy for decompensated CHF is not proarrhythmic [abstract]. J Am Coll Cardiol 2000;35:172A.
47. Stevenson L, on behalf of the VMAC Study Group. The effects of nesiritide (B-type natriuretic peptide) and intravenous nitroglycerin on pulmonary and systemic pressures in decompensated heart failure [abstract]. J Card Fail 2001;7:55.
48. Elkayam U, Group VS. Superior hemodynamic effect of nesiritide (B-type natriuretic peptide) compared to high dose nitroglycerin (NTG) in patients with decompensated heart failure: National Association of Inpatient Physicians Fifth Annual Meeting 2002 [abstract]. Research and Clinical Vignette 2002;7.
49. Abraham W, on behalf of the VMAC Investigators. Effects of nesiritide (B-type natriuretic peptide) in decompensated heart failure patients receiving beta-blockers [abstract]. Circulation 2001;104: II-420.
50. Elkayam U, Group VS. The lack of ischemic cardiovascular adverse events with nesiritide (B-type natriuretic peptide) and nitroglycerin in the treatment of acute heart failure [abstract]. J Cardiac Fail 2001;73:59.
51. Zellner C, Protter AA, Ko E, et al. Coronary vasodilator effects of BNP: mechanisms of action in coronary conductance and resistance arteries. Am J Phys 1999;276(Suppl):H1049-57.
52. Cuffe MS, Califf RM, Adams KF, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure. JAMA 2002;287:1541-7.
53. Johnson W, Omland T, Holl C, et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 2002;39:1623-9.